Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

J Thorac Oncol. 2020 Jan;15(1):12-14. doi: 10.1016/j.jtho.2019.10.017.

¹ Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute; Department of Medical Oncology, Austin Health; and the School of Cancer Medicine, La Trobe University, Heidelberg, Australia. Electronic address: surein.arulananda@onjcri.org.au.
² Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute; Department of Medical Oncology, Austin Health; and the School of Cancer Medicine, La Trobe University, Heidelberg, Australia.

No abstract available

Publication types